ArticleThe Lancet regional health. Western Pacific2025
Genetic factors driving the
Article in The Lancet regional health. Western Pacific, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Genomic Surveillance Reveals Emergence and Spread of Macrolide-Resistant Mycoplasma pneumoniae in Australia During the 2023-2024 Epidemic.The Journal of infectious diseases · 2026Article
- Reconstructing the post-pandemic landscape: a retrospective, hospital-based surveillance of respiratory pathogens in hospitalized children in Chenzhou, China, 2021-2025.BMC infectious diseases · 2026Article
- Epidemiological Characteristics of Respiratory Syncytial Virus in Pediatric Acute Lower Respiratory Tract Infections in Baoding, Hebei Province of China, from 2017 to 2024.Children (Basel, Switzerland) · 2026Article
- High-Risk CCL14 lineage drives severe Mycoplasma pneumoniae pneumonia in children: a study in central China.Clinical and experimental pediatrics · 2026Article
- Emergence of Clinically Macrolide-UnresponsiveAntibiotics (Basel, Switzerland) · 2026Article
- The Post-Pandemic Return ofJournal of clinical medicine · 2026Article
- Macrolide Resistance and Multilocus Sequence Typing Genotype Analysis ofPublic health weekly report · 2026Article
- Genomic epidemiology and antimicrobial susceptibility of clinicalFrontiers in cellular and infection microbiology · 2026Article
- Analysis of Clinical Characteristics and Risk Factors of Pediatric Macrolide-ResistantInfection and drug resistance · 2026Article
- Host inflammatory markers and MLVA profiling for risk assessment of severe pediatricFrontiers in cellular and infection microbiology · 2026Article
- Immune dysregulation inFrontiers in immunology · 2026Review
- From genes to clinical application: a circulating four-gene signature for early diagnosis model of refractoryFrontiers in cellular and infection microbiology · 2026Article
- Macrolide Resistance ofInfection and drug resistance · 2026Article
- Macrolide-Resistant Mycoplasma pneumoniae in Children, Ohio, USA.Emerging infectious diseases · 2025Article
- Clonal replacement by a P1-1/ST3 lineage in pediatricFrontiers in cellular and infection microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Methods: We performed whole-genome sequencing on 169 Findings: We identified a post-COVID-19 resurgence of Interpretation: This study provides a comprehensive genomic analysis of genetic factors driving the outbreak. With near-100% macrolide resistance in China, urgent changes in treatment policies are needed. The rising prevalence of 4-5-7-2 and its functional advantages warrant close monitoring. Our findings offer insights into the outbreak causes and guide future prevention and control strategies. Funding: National Key R&D Program of China; Training Plan for High level Public Health Technical Talents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.